# Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma

> **NCT05930665** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 38 (estimated)

## Conditions studied

- Pleural Mesothelioma

## Interventions

- **DRUG:** Cadonilimab+Bevacizumab+Pemetrexed+Carboplatin

## Key facts

- **NCT ID:** NCT05930665
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-11-01
- **Primary completion:** 2025-07
- **Final completion:** 2026-07
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05930665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05930665, "Study of Cadonilimab Combined With Bevacizumab and Standard Chemotherapy as First Line Therapy in Unresectable Pleural Mesothelioma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05930665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*